Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hansa Biopharma in connection with a directed share issue
Mandate

Vinge advises Hansa Biopharma in connection with a directed share issue

July 13, 2020

The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Hansa Biopharma will raise proceeds of SEK 1.1 billion, before issue costs.

The share issue was made on the basis of an accelerated bookbuilding process carried out by Morgan Stanley, Kempen & Co and Zonda Partners, and was multiple times oversubscribed due to high demand from US, European and Swedish institutional investors.

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)- mediated autoimmune conditions, transplant rejection and cancer.

Vinge’s team consisted of Dain Hård Nevonen, Malte St Cyr Ohm, Stephanie Stiernstedt and Hampus Olsson.

 

The Swedish rules on cabotage transport and posting will change on 2 and 21 February 2022

 The Swedish government has decided on a number of new rules concerning cabotage transports, combined transports, transport customer responsibility for driving and rest times and posting of workers.
January 21, 2022

Vinge presents the Swedish chapter for the 2022 version of The Legal 500: Private Equity Country Comparative Guide

 The guide provides an overview of the Swedish Private Equity market and the salient legislation in connection with PE transactions in Sweden.
January 11, 2022

The prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings

 On Tuesday 21 December, the EU Court of Justice delivered its long-awaited judgment in the Bank Melli Iran case (Case C-124/20) on the interpretation of the EU Blocking Statute regarding compliance with third country sanctions. According to the Court, the prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings. Following the Court’s judgment, anyone seeking to terminate a contract with a person or business subject to US sanctions must thoroughly consider if the termination is motivated by other reasons than the existing sanctions and reflect on whether to apply to the Commission for a derogation from the Blocking Statute.
December 23, 2021